Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162877 | 0.81 | CYP3A4 (0.40) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL30438482 | 0.81 | CYP3A4 (0.40) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL28565927 | 0.81 | CYP3A4 (0.52) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL28152465 | 0.81 | CYP3A4 (0.52) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL110655 | 0.80 | CYP3A4 (0.73) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31162473 | 0.80 | CYP3A4 (0.73) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL4774932 | 0.80 | CYP3A4 (0.45) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL3550575 | 0.80 | CYP3A4 (0.36) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL2956221 | 0.78 | CYP3A4 (0.48) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL1996908 | 0.78 | CYP3A4 (0.47) | CYP3A4TRPA1ALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124759-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2150553-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090023743-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (IL) | 2009-01-22 | — | — | US | disclosed |
| WO-2008141145-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141140-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | AURKC, AURKB, PLK1 | CYP3A4 4679/4885TRPA1 4801/4885ALDH1A1 4309/4885 |
| US-20090023743-A1 | INHIBITORS OF PROTEIN KINASES | AURKC, AURKB, PLK1 | CYP3A4 4679/4885TRPA1 4801/4885ALDH1A1 4309/4885 |
| US-20050239841-A1 | New compounds | MCHR1, NPY1R, HCRTR1 | CYP3A4 1263/4885TRPA1 467/4885ALDH1A1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.